← Back to Screener
Disc Medicine, Inc. Common Stock (IRON)
Price$67.00
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)-36.16%
Price vs S&P 500 (4W)-1.84%
VGM Score68.57
Market Capitalization$2.56B
All Metrics
Book Value / Share (Quarterly)$18.03
P/TBV (Annual)7.35x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-5.27
Price vs S&P 500 (YTD)-23.79%
EPS (TTM)$-6.61
10-Day Avg Trading Volume0.40M
EPS Excl Extra (TTM)$-6.61
EPS (Annual)$-6.01
ROI (Annual)-23.17%
Cash / Share (Quarterly)$19.12
ROA (Last FY)-22.00%
EBITD / Share (TTM)$-7.25
ROE (5Y Avg)-26.32%
Cash Flow / Share (Annual)$-3.15
P/B Ratio3.72x
P/B Ratio (Quarterly)3.54x
Net Income / Employee (Annual)$-1,368,900
Net Interest Coverage (TTM)-32.58x
ROA (TTM)-33.88%
EPS Incl Extra (Annual)$-6.01
Current Ratio (Annual)21.48x
Quick Ratio (Quarterly)23.45x
3-Month Avg Trading Volume0.59M
52-Week Price Return39.55%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$14.87
52-Week High$99.50
EPS Excl Extra (Annual)$-6.01
26-Week Price Return-28.23%
Quick Ratio (Annual)21.32x
13-Week Price Return11.04%
Total Debt / Equity (Annual)0.06x
Current Ratio (Quarterly)24.00x
Enterprise Value$2.50B
Revenue / Employee (Annual)$0
Cash / Share (Annual)$16.33
3-Month Return Std Dev40.14%
Net Income / Employee (TTM)$-1,558,700
ROE (Last FY)-24.63%
Net Interest Coverage (Annual)-188.03x
EPS Basic Excl Extra (Annual)$-6.01
Total Debt / Equity (Quarterly)0.04x
EPS Incl Extra (TTM)$-6.61
ROI (TTM)-35.37%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$10.15
Price vs S&P 500 (52W)15.19%
Year-to-Date Return-15.63%
5-Day Price Return-6.91%
EPS Normalized (Annual)$-6.01
ROA (5Y Avg)-23.60%
Month-to-Date Return-3.69%
Cash Flow / Share (TTM)$-3.60
EBITD / Share (Annual)$-6.68
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-25.55%
LT Debt / Equity (Quarterly)0.04x
EPS Basic Excl Extra (TTM)$-6.61
P/TBV (Quarterly)3.62x
P/B Ratio (Annual)4.25x
Book Value / Share (Annual)$14.80
Price vs S&P 500 (13W)2.78%
Beta1.02x
Revenue / Share (TTM)$0.00
ROE (TTM)-36.95%
52-Week Low$40.00
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-1.65est. -1.75
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.32
4.32
4.32
4.32
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
IRONDisc Medicine, Inc. Common Stock | — | — | B | $67.00 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Disc Medicine is a clinical-stage biopharmaceutical company developing treatments for hematologic disorders through modulation of heme biosynthesis and iron homeostasis. The company's pipeline includes bitopertin for erythropoietic porphyrias, DISC-0974 for anemia in myelofibrosis and chronic kidney disease, and DISC-3405 for polycythemia vera. These programs target conditions with significant unmet medical needs and substantial market opportunities.